This company has shut down. Ultimovacs is no longer operating — its last tracked round was a Post-IPO Equity in 2021.
Explore the Startup GraveyardUltimovacs is a pharmaceutical company developing novel immunotherapies against cancer.
Ultimovacs has raised $32.3M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2021.
Ultimovacs is headquartered in Oslo, Norway.
Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer.
Ultimovacs is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ultimovacs — Funding & Investors." VCBacked, October 26, 2021, https://www.vcbacked.co/company/ultimovacs. Accessed August 14, 2026.
VCBacked. (2021). Ultimovacs — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/ultimovacs
{{cite web |title=Ultimovacs — Funding & Investors |url=https://www.vcbacked.co/company/ultimovacs |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated